2025/05/07 更新

お知らせ

 

写真a

ナカノ　ヤスヒロ
仲野 泰啓
NAKANO YASUHIRO
所属
九州大学病院 循環器内科 助教
九州大学病院 循環器内科（併任）
医学部 医学科（併任）
職名
助教
連絡先
メールアドレス
電話番号
0926425360
プロフィール
循環器内科一般 冠動脈インターベンション治療 末梢動脈インターベンション治療 心臓CT 臨床研究
ホームページ
外部リンク

研究分野

  • ライフサイエンス / 循環器内科学

学位

  • 医学博士

経歴

  • 九州大学 循環器内科 助教 

    2022年4月 - 現在

研究テーマ・研究キーワード

  • 研究テーマ： 冠動脈インターベンション 心臓CT 冠動脈石灰化

    研究キーワード： 冠動脈インターベンション, 心臓CT, 冠動脈石灰化

    研究期間： 2023年6月

論文

  • JCS/JCC/JACR/JATS 2024 Guideline on Cardiovascular Practice With Consideration for Diversity, Equity, and Inclusion.

    Tsukada YT, Aoki-Kamiya C, Mizuno A, Nakayama A, Ide T, Aoyama R, Honye J, Hoshina K, Ikegame T, Inoue K, Bando YK, Kataoka M, Kondo N, Maemura K, Makaya M, Masumori N, Mito A, Miyauchi M, Miyazaki A, Nakano Y, Nakao YM, Nakatsuka M, Nakayama T, Oginosawa Y, Ohba N, Otsuka M, Okaniwa H, Saito A, Saito K, Sakata Y, Harada-Shiba M, Soejima K, Takahashi S, Takahashi T, Tanaka T, Wada Y, Watanabe Y, Yano Y, Yoshida M, Yoshikawa T, Yoshimatsu J, Abe T, Dai Z, Endo A, Fukuda-Doi M, Ito-Hagiwara K, Harima A, Hirakawa K, Hosokawa K, Iizuka G, Ikeda S, Ishii N, Izawa KP, Kagiyama N, Umeda-Kameyama Y, Kanki S, Kato K, Komuro A, Konagai N, Konishi Y, Nishizaki F, Noma S, Norimatsu T, Numao Y, Oishi S, Okubo K, Ohmori T, Otaki Y, Shibata T, Shibuya J, Shimbo M, Shiomura R, Sugiyama K, Suzuki T, Tajima E, Tsukihashi A, Yasui H, Amano K, Kohsaka S, Minamino T, Nagai R, Setoguchi S, Terada K, Yumino D, Tomoike H, Japanese Circulation Society Joint Working Group

    Circulation journal : official journal of the Japanese Circulation Society   89 ( 5 )   658 - 739   2025年4月   （ ISSN:1346-9843 ）

    　詳細を見る

    記述言語：英語  

    DOI： 10.1253/circj.CJ-23-0890

    PubMed

  • Spontaneous coronary artery dissection in a male patient with haemophilia A: a case report. 査読

    Kimura M, Nakano Y, Abe K, Matoba T.

    Eur Heart J Case Rep.   2025年4月

    　詳細を見る

    記述言語：英語  

    DOI： 10.1093/ehjcr/ytaf196.

  • Effect of PCSK9 inhibitor usage on coronary endothelial dysfunction in patients with hypercholesterolemia after coronary stenting: The CuVIC-2 trial.

    Akiyama Y, Katsuki S, Koga Y, Yamamoto M, Hironaga K, Suematsu N, Miyata K, Mukai Y, Inoue S, Nishi JI, Tashiro H, Nakano Y, Funakoshi K, Tagawa K, Ichi I, Tsutsui H, Abe K, Matoba T

    Journal of cardiology   2025年4月   （ ISSN:0914-5087 ）

    　詳細を見る

    記述言語：英語  

    DOI： 10.1016/j.jjcc.2025.04.002

    PubMed

  • T. Effect of PCSK9 inhibitor usage on coronary endothelial dysfunction in patients with hypercholesterolemia after coronary stenting: The CuVIC-2 trial. 査読

    Akiyama Y, Katsuki S, Koga Y, Yamamoto M, Hironaga K, Suematsu N, Miyata K, Mukai Y, Inoue S, Nishi JI, Tashiro H, Nakano Y, Funakoshi K, Tagawa K, Ichi I, Tsutsui H, Abe K, Matoba T.

    J Cardiol.   2025年4月

    　詳細を見る

    担当区分：責任著者   記述言語：英語  

    DOI： 10.1016/j.jep.2011.06.041.

  • Spontaneous coronary artery dissection in a male patient with haemophilia A: a case report

    Kimura, M; Nakano, Y; Abe, K; Matoba, T

    EUROPEAN HEART JOURNAL-CASE REPORTS   9 ( 4 )   ytaf196   2025年4月   （ eISSN:2514-2119 ）

    　詳細を見る

  • Achievement of guideline-recommended target blood pressure is associated with reducing the risk of hemorrhagic and ischemic stroke in Japanese coronary artery disease patients: the CLIDAS study(タイトル和訳中)

    Oba Yusuke, Kabutoya Tomoyuki, Kohro Takahide, Imai Yasushi, Kario Kazuomi, Sato Hisahiko, Nochioka Kotaro, Nakayama Masaharu, Akashi Naoyuki, Fujita Hideo, Mizuno Yoshiko, Kiyosue Arihiro, Iwai Takamasa, Miyamoto Yoshihiro, Nakano Yasuhiro, Ishii Masanobu, Nakamura Taishi, Tsujita Kenichi, Matoba Tetsuya, Nagai Ryozo

    Hypertension Research   48 ( 2 )   632 - 639   2025年2月   （ ISSN:0916-9636 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：Nature Publishing Group  

  • Achievement of guideline-recommended target blood pressure is associated with reducing the risk of hemorrhagic and ischemic stroke in Japanese coronary artery disease patients -the CLIDAS study-

    Oba, Y; Kabutoya, T; Kohro, T; Imai, Y; Kario, K; Sato, H; Nochioka, K; Nakayama, M; Akashi, N; Fujita, H; Mizuno, Y; Kiyosue, A; Iwai, T; Miyamoto, Y; Nakano, Y; Ishii, M; Nakamura, T; Tsujita, K; Matoba, T; Nagai, R

    HYPERTENSION RESEARCH   48 ( 2 )   632 - 639   2025年2月   （ ISSN:0916-9636 eISSN:1348-4214 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：Hypertension Research  

    The Japanese Society of Hypertension have established a blood pressure (BP) target of 130/80 mmHg for patients with coronary artery disease (CAD). We evaluated the data of 8793 CAD patients in the Clinical Deep Data Accumulation System database who underwent cardiac catheterization at six university hospitals and the National Cerebral and Cardiovascular Center (average age 70 ± 11 years, 78% male, 43% with acute coronary syndrome [ACS]). Patients were divided into two groups based on whether or not they achieved the guideline-recommended BP of <130/80 mmHg. We analyzed the relationship between BP classification and major adverse cardiac and cerebral event (MACCE) separately in two groups: those with ACS and those with chronic coronary syndrome (CCS). During an average follow-up period of 33 months, 710 MACCEs occurred. A BP below 130/80 mmHg was associated with fewer MACCEs in both the overall (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.70–1.00, p = 0.048) and the ACS group (HR 0.67, 95%CI 0.51–0.88, p = 0.003). In particular, stroke events were also lower among those with a BP below 130/80 mmHg in both the overall (HR 0.69, 95%CI 0.53–0.90, p = 0.006) and ACS groups (HR 0.44, 95%CI 0.30–0.67, p < 0.001). In conclusion, the achievement of BP guidelines was associated with improved outcomes in CAD patients, particularly in reducing stroke risk among those with ACS. (Figure presented.)

    DOI： 10.1038/s41440-024-01902-5

    Web of Science

    Scopus

    PubMed

  • "LIPID PARADOX" IN JAPANESE HYPERTRIGLYCERIDEMIA PATIENTS UNDERGOING PCI IN CLIDAS

    Kimura, M; Katsuki, S; Nakano, Y; Kawahara, T; Hino, R; Tabuchi, T; Fukata, M; Hieda, M; Kohro, T; Kabutoya, T; Makimoto, H; Kario, K; Imai, Y; Fujita, H; Kodera, S; Kiyosue, A; Nakayama, M; Miyamoto, Y; Tsujita, K; Sato, H; Nagai, R; Matoba, T

    ATHEROSCLEROSIS   399   2024年12月   （ ISSN:0021-9150 eISSN:1879-1484 ）

    　詳細を見る

  • Predictors of debulking devices use by coronary artery calcification classification using cardiac CT

    Nakano, Y; Okutsu, M; Sadamatsu, K; Nagata, T; Serikawa, T; Hasegawa, K; Fujimoto, Y; Yamada, S; Takahashi, Y; Kurogi, K; Masuda, N; Nakano, M; Torii, S; Tanabe, M; Matoba, T

    EUROPEAN HEART JOURNAL   45   2024年10月   （ ISSN:0195-668X eISSN:1522-9645 ）

    　詳細を見る

  • Clinical Deep Data Accumulation System (CLIDAS) reveals a "Lipid paradox" of hypertriglyceridemia in Japanese patients

    Katsuki, S; Kawahara, T; Nakano, Y; Kimura, M; Rissei, H; Matoba, T

    EUROPEAN HEART JOURNAL   45   2024年10月   （ ISSN:0195-668X eISSN:1522-9645 ）

    　詳細を見る

  • Achievement of guideline-recommended target blood pressure is associated with reducing the risk of hemorrhagic and ischemic stroke in Japanese coronary artery disease patients -the CLIDAS study. 査読

    Oba Y, Kabutoya T, Kohro T, Imai Y, Kario K, Sato H, Nochioka K, Nakayama M, Akashi N, Fujita H, Mizuno Y, Kiyosue A, Iwai T, Miyamoto Y, Nakano Y, Ishii M, Nakamura T, Tsujita K, Matoba T, Nagai R

    Hypertens Res.   2024年9月

    　詳細を見る

    担当区分：責任著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1038/s41440-024-01902-5.

  • Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on the Severity and the Mortality of Acute Myocardial Infarction in Japan - Analysis From the JROAD-DPC Database.

    Kimura M, Matoba T, Nakano Y, Katsuki S, Sakamoto K, Nishihara M, Nagata T, Tahara Y, Nagao K, Okura H, Ikeda T, Nakai M, Tsutsui H.

    Circ Rep.   2024年5月

  • Overview of the 87th Annual Scientific Meeting of the Japanese Circulation Society (JCS2023) : New Challenge With Next Generation

    Matoba, T; Nakano, Y; Katsuki, S; Ide, T; Matsushima, S; Fujino, T; Hashimoto, T; Shinohara, K; Abe, K; Hosokawa, K; Sakamoto, T; Sakamoto, I; Kakino, T; Ishikita, A; Nishizaki, A; Sakamoto, K; Takase, S; Nagayama, T; Tohyama, T; Nagata, T; Kinugawa, S; Tsutsui, H

    CIRCULATION JOURNAL   88 ( 4 )   615 - 619   2024年3月   （ ISSN:13469843 eISSN:13474820 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：一般社団法人 日本循環器学会  

    The 87th Annual Meeting of the Japanese Circulation Society (JCS2023) was held in March 2023 in Fukuoka, Japan, marking the first in-person gathering after the COVID-19 pandemic. With the theme of “New Challenge With Next Generation” the conference emphasized the development of future cardiovascular leaders and technologies such as artificial intelligence (AI). Notable sessions included the Mikamo Lecture on heart failure and the Mashimo Lecture on AI in medicine. Various hands-on sessions and participatory events were well received, promoting learning and networking. Post-event surveys showed high satisfaction among participants, with positive feedback on face-to-face interactions and the overall experience. JCS2023, attended by 17,852 participants, concluded successfully, marking a significant milestone in post-pandemic meetings, and advancing cardiovascular medicine.

    DOI： 10.1253/circj.cj-24-0127

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction

    Hokimoto, S; Kaikita, K; Yasuda, S; Tsujita, K; Ishihara, M; Matoba, T; Matsuzawa, Y; Mitsutake, Y; Mitani, Y; Murohara, T; Noda, T; Node, K; Noguchi, T; Suzuki, H; Takahashi, J; Tanabe, Y; Tanaka, A; Tanaka, N; Teragawa, H; Yasu, T; Yoshimura, M; Asaumi, Y; Godo, S; Ikenaga, H; Imanaka, T; Ishibashi, K; Ishii, M; Ishihara, T; Matsuura, Y; Miura, H; Nakano, Y; Ogawa, T; Shiroto, T; Soejima, H; Takagi, R; Tanaka, A; Tanaka, A; Taruya, A; Tsuda, E; Wakabayashi, K; Yokoi, K; Minamino, T; Nakagawa, Y; Sueda, S; Shimokawa, H; Ogawa, H

    JOURNAL OF CARDIOLOGY   82 ( 4 )   293 - 341   2023年10月   （ ISSN:0914-5087 eISSN:1876-4738 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：Journal of Cardiology  

    DOI： 10.1016/j.jjcc.2023.06.009

    Web of Science

    Scopus

    PubMed

  • Oxysterol: Residual Lipid Risk for Interventional Cardiology

    Nakano, Y; Yamamoto, M; Matoba, T; Katsuki, S; Nakashiro, S; Takase, S; Akiyama, Y; Nagata, T; Mukai, Y; Inoue, S; Oi, K; Higo, T; Takemoto, M; Suematsu, N; Eshima, K; Miyata, K; Usui, M; Sadamatsu, K; Kadokami, T; Hironaga, K; Ichi, I; Todaka, K; Kishimoto, J; Tsutsui, H

    Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ   30 ( 8 )   907 - 918   2023年8月   （ ISSN:13403478 eISSN:18803873 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：一般社団法人 日本動脈硬化学会  

    Aim: Several clinical trials using intravascular ultrasound (IVUS) evaluation have demonstrated that intensive lipid-lowering therapy by statin or a combination therapy with statin and ezetimibe results in significant regression of coronary plaque volume. However, it remains unclear whether adding ezetimibe to statin therapy affects coronary plaque composition and the molecular mechanisms of plaque regression. We conducted this prospective IVUS analysis in a subgroup from the CuVIC trial. Methods: The CuVIC trial was a prospective randomized, open, blinded-endpoint trial conducted among 11 cardiovascular centers, where 260 patients with coronary artery disease who received coronary stenting were randomly allocated into either the statin group (S) or the combined statin and ezetimibe group (S＋E). We enrolled 79 patients (S group, 39 patients; S＋E group, 40 patients) in this substudy, for whom serial IVUS images of nonculprit lesion were available at both baseline and after 6–8 months of follow-up. Results: After the treatment period, the S＋E group had significantly lower level of low-density lipoprotein cholesterol (LDL-C; 80.9±3.7 vs. 67.7±3.8 mg/dL, p=0.0143). Campesterol, a marker of cholesterol absorption, and oxysterols (β-epoxycholesterol, 4β-hydroxycholesterol, and 27-hydroxycholesterol) were also lower in the S ＋E group. IVUS analyses revealed greater plaque regression in the S＋E group than in the S group (−6.14% vs. −1.18% for each group, p =0.042). It was noteworthy that the lowering of campesterol and 27-hydroxycholesterol, but not LDL-C, had a significant positive correlation with plaque regression. Conclusions: Compared with statin monotherapy, ezetimibe in combination with statin achieved significantly lower LDL-C, campesterol, and 27-hydroxycholesterol, which resulted in greater coronary plaque regression.

    DOI： 10.5551/jat.63507

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • スタチンおよびエゼチミブによる脂質低下療法中の血清オキシステロールと冠動脈プラーク退縮との関連性　CuVIC試験からの知見(Association between Serum Oxysterols and Coronary Plaque Regression during Lipid-Lowering Therapy with Statin and Ezetimibe: Insights from the CuVIC Trial)

    Nakano Yasuhiro, Yamamoto Mitsutaka, Matoba Tetsuya, Katsuki Shunsuke, Nakashiro Soichi, Takase Susumu, Akiyama Yusuke, Nagata Takuya, Mukai Yasushi, Inoue Shujiro, Oi Keiji, Higo Taiki, Takemoto Masao, Suematsu Nobuhiro, Eshima Kenichi, Miyata Kenji, Usui Makoto, Sadamatsu Kenji, Kadokami Toshiaki, Hironaga Kiyoshi, Ichi Ikuyo, Todaka Koji, Kishimoto Junji, Tsutsui Hiroyuki

    Journal of Atherosclerosis and Thrombosis   30 ( 8 )   907 - 918   2023年8月   （ ISSN:1340-3478 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本動脈硬化学会  

    冠動脈ステント留置術を受けた冠動脈疾患の患者をスタチン(S)またはSとエゼチミブの併用(S+E)で治療するCuVIC試験から、治療前と6～8ヵ月追跡調査後の非責任病変の血管内超音波(IVUS)画像が得られた79症例(S群39名、S+E群40名)を抽出し解析した。治療期間後のS+E群のLDL-コレステロール(LDL-C)値はS群と比べて有意に低かった。S+E群ではコレステロール吸収のマーカーであるcampesterol、オキシステロール(β-epoxycholesterol、4β-hydroxycholesterol、27-hydroxycholesterol)も低かった。IVUS解析でS+E群のプラーク退縮率はS群と比べて大きかった。campesterolおよび27-hydroxycholesterolの低下はプラーク退縮と正相関し、LDL-Cの低下は相関しなかった。

  • Temporal Trends in Antithrombotic Therapy for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention From 2014 to 2022 in Japan

    Nakano, Y; Matoba, T; Yamamoto, M; Katsuki, S; Koga, Y; Mukai, Y; Inoue, S; Suematsu, N; Higo, T; Takemoto, M; Miyata, K; Usui, M; Kadokami, T; Tashiro, H; Morishige, K; Hironaga, K; Tsutsui, H

    Circulation Reports   5 ( 7 )   282 - 288   2023年7月   （ eISSN:24340790 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：一般社団法人 日本循環器学会  

    <p><b><i>Background:</i></b> Recent revisions of clinical guidelines by the Japanese Circulation Society, American Heart Association/American College of Cardiology, and European Society of Cardiology updated the management of antithrombotic strategies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, the extent to which these guidelines have been implemented in real-world daily clinical practice is unclear.</p><p><b><i>Methods and Results:</i></b> We conducted surveys on the status of antithrombotic therapy for patients with AF undergoing PCI every 2 years from 2014 to 2022 in 14 cardiovascular centers in Japan. The primary use of drug-eluting stents increased from 10% in 2014 to 95–100% in 2018, and the use of direct oral anticoagulants increased from 15% in 2014 to 100% in 2018, in accordance with the revised practice guidelines. In patients with acute coronary syndrome, the duration of triple therapy within 1 month was approximately 10% until 2018, and increased to >70% from 2020. In patients with chronic coronary syndrome, the duration of triple therapy within 1 month was approximately 10% until 2016, and >75% from 2018. Since 2020, the most common timing of discontinuation of dual antiplatelet therapy to transition to anticoagulation monotherapy during the chronic phase of PCI has been 1 year after PCI.</p><p><b><i>Conclusions:</i></b> Japanese interventional cardiologists have updated their treatment strategies for patients with AF undergoing PCI according to revisions of clinical practice guidelines.</p>

    DOI： 10.1253/circrep.cr-23-0047

    Web of Science

    PubMed

    CiNii Research

  • 国内で経皮的冠動脈インターベンションを受ける心房細動患者への抗血栓療法に関する2014～2022年の経時的傾向(Temporal Trends in Antithrombotic Therapy for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention From 2014 to 2022 in Japan)

    Nakano Yasuhiro, Matoba Tetsuya, Yamamoto Mitsutaka, Katsuki Shunsuke, Koga Yasuaki, Mukai Yasushi, Inoue Shujiro, Suematsu Nobuhiro, Higo Taiki, Takemoto Masao, Miyata Kenji, Usui Makoto, Kadokami Toshiaki, Tashiro Hideki, Morishige Kunio, Hironaga Kiyoshi, Tsutsui Hiroyuki

    Circulation Reports   5 ( 7 )   282 - 288   2023年7月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本循環器学会  

    日本国内の心血管センター14施設において経皮的冠動脈インターベンション(PCI)を受ける心房細動(AF)患者への抗血栓療法の状況を、2014～2022年にかけて2年毎に調査した。本大学の協力施設である上記14施設の心臓インターベンション専門医(CI医)に対し、PCIを施行されるAF症例への抗血栓療法について2年置きの質問票調査を行った。薬剤溶出ステントを初回使用すると回答された率は2014年の10%から2018年には95～100%へ、直接経口抗凝固薬の使用は2014年の15%から2018年には100%へと上昇していた。これらの使用率上昇の動向は、最近改訂された、日本・米国・欧州の3学会による臨床ガイドラインに沿ったものであった。急性冠症候群の患者のシナリオを提示した場合、3剤併用療法を施行する期間の長さを1ヵ月以内と回答した率は2018年までは10%であったのに対し、2020年は70%超へと上昇していた。慢性冠症候群のシナリオでは、上記の回収率は2016年までは約10%、2018年以降は75%超へ上昇した。PCIの慢性期に抗血小板薬2剤併用療法を中止し単剤療法へと移行するタイミングとして、2020年以降、最も回答が多かったのは、PCI後1年であった。日本のCI医は、臨床診療ガイドラインの改訂に合わせ、PCI施行AF患者に対しての自身の治療戦略も最新のものに更新していた。

  • Association of Serum Oxysterols with Cholesterol Metabolism Markers and Clinical Factors in Patients with Coronary Artery Disease: A Covariance Structure Analysis

    Akiyama, Y; Katsuki, S; Matoba, T; Nakano, Y; Takase, S; Nakashiro, S; Yamamoto, M; Mukai, Y; Inoue, S; Oi, K; Higo, T; Takemoto, M; Suematsu, N; Eshima, K; Miyata, K; Usui, M; Sadamatsu, K; Kadokami, T; Hironaga, K; Ichi, I; Todaka, K; Kishimoto, J; Tsutsui, H

    NUTRIENTS   15 ( 13 )   2023年7月   （ eISSN:2072-6643 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：Nutrients  

    Oxysterols have been implicated in the pathogenesis of cardiovascular diseases. Serum levels of oxysterols could be positively correlated with cholesterol absorption and synthesis. However, physiological regulation of various serum oxysterols is largely unknown. The aim of this study was to investigate the relationship between clinical factors and cholesterol metabolism markers, and identify oxysterols associated with cholesterol absorption and synthesis in patients with coronary artery disease. Subjects (n = 207) who underwent coronary stenting between 2011 and 2013 were studied cross-sectionally. We measured lipid profiles including serum oxysterols. As for the serum biomarkers of cholesterol synthesis and absorption, oxysterol levels were positively correlated with campesterol and lathosterol. Covariance structure analysis revealed that dyslipidemia and statin usage had a positive correlation with “cholesterol absorption”. Statin usage also had a positive correlation with “cholesterol synthesis”. Several oxysterols associated with cholesterol absorption and/or synthesis. In conclusion, we elucidated the potential clinical factors that may affect cholesterol metabolism, and the associations between various oxysterols with cholesterol absorption and/or synthesis in patients with coronary artery disease.

    DOI： 10.3390/nu15132997

    Web of Science

    Scopus

    PubMed

  • 特集 MINOCAの病態･診断･治療 INOCA/MINOCAと心不全

    的場 哲哉, 仲野 泰啓, 筒井 裕之

    医学のあゆみ   285 ( 11 )   1010 - 1013   2023年6月   （ ISSN:00392359 ）

    　詳細を見る

    出版者・発行元：医歯薬出版  

    DOI： 10.32118/ayu285111010

    CiNii Research

  • Temporal Trends in Antithrombotic Therapy for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention From 2014 to 2022 in Japan.

    Nakano Y, Matoba T, Yamamoto M, Katsuki S, Koga Y, Mukai Y, Inoue S, Suematsu N, Higo T, Takemoto M, Miyata K, Usui M, Kadokami T, Tashiro H, Morishige K, Hironaga K, Tsutsui H; for the QcVIC Investigators

    Circ Rep.   2023年6月

  • Association of Serum Oxysterols with Cholesterol Metabolism Markers and Clinical Factors in Patients with Coronary Artery Disease: A Covariance Structure Analysis.

    Akiyama Y, Katsuki S, Matoba T, Nakano Y, Takase S, Nakashiro S, Yamamoto M, Mukai Y, Inoue S, Oi K, Higo T, Takemoto M, Suematsu N, Eshima K, Miyata K, Usui M, Sadamatsu K, Kadokami T, Hironaga K, Ichi I, Todaka K, Kishimoto J, Tsutsui H.

    Nutrients.   2023年5月

  • JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction

    Hokimoto, S; Kaikita, K; Yasuda, S; Tsujita, K; Ishihara, M; Matoba, T; Matsuzawa, Y; Mitsutake, Y; Mitani, Y; Murohara, T; Noda, T; Node, K; Noguchi, T; Suzuki, H; Takahashi, J; Tanabe, Y; Tanaka, A; Tanaka, N; Teragawa, H; Yasu, T; Yoshimura, M; Asaumi, Y; Godo, S; Ikenaga, H; Imanaka, T; Ishibashi, K; Ishii, M; Ishihara, T; Matsuura, Y; Miura, H; Nakano, Y; Ogawa, T; Shiroto, T; Soejima, H; Takagi, R; Tanaka, A; Tanaka, A; Taruya, A; Tsuda, E; Wakabayashi, K; Yokoi, K; Minamino, T; Nakagawa, Y; Sueda, S; Shimokawa, H; Ogawa, H

    CIRCULATION JOURNAL   87 ( 6 )   879 - 936   2023年5月   （ ISSN:13469843 eISSN:13474820 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：一般社団法人 日本循環器学会  

    DOI： 10.1253/circj.cj-22-0779

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction.

    Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, Matsuzawa Y, Mitsutake Y, Mitani Y, Murohara T, Noda T, Node K, Noguchi T, Suzuki H, Takahashi J, Tanabe Y, Tanaka A, Tanaka N, Teragawa H, Yasu T, Yoshimura M, Asaumi Y, Godo S, Ikenaga H, Imanaka T, Ishibashi K, Ishii M, Ishihara T, Matsuura Y, Miura H, Nakano Y, Ogawa T, Shiroto T, Soejima H, Takagi R, Tanaka A, Tanaka A, Taruya A, Tsuda E, Wakabayashi K, Yokoi K, Minamino T, Nakagawa Y, Sueda S, Shimokawa H, Ogawa H

    Circ J.   2023年5月

  • Relationships Among Heart Rate, β-Blocker Dosage, and Prognosis in Patients With Coronary Artery Disease in a Real-World Database Using a Multimodal Data Acquisition System.

    Yusuke Oba, Tomoyuki Kabutoya, Takahide Kohro, Yasushi Imai, Kazuomi Kario, Hisahiko Sato, Kotaro Nochioka, Masaharu Nakayama, Hideo Fujita, Yoshiko Mizuno, Arihiro Kiyosue, Takamasa Iwai, Yoshihiro Miyamoto, Yasuhiro Nakano, Taishi Nakamura, Kenichi Tsujita, Tetsuya Matoba, Ryozo Nagai,

    Circ J.   2023年1月

  • マルチモーダルデータ収集システムを使用した実臨床データベースに登録されている冠動脈疾患患者における心拍数、β遮断薬投与量、予後の関連性(Relationships Among Heart Rate, β-Blocker Dosage, and Prognosis in Patients With Coronary Artery Disease in a Real-World Database Using a Multimodal Data Acquisition System)

    Oba Yusuke, Kabutoya Tomoyuki, Kohro Takahide, Imai Yasushi, Kario Kazuomi, Sato Hisahiko, Nochioka Kotaro, Nakayama Masaharu, Fujita Hideo, Mizuno Yoshiko, Kiyosue Arihiro, Iwai Takamasa, Miyamoto Yoshihiro, Nakano Yasuhiro, Nakamura Taishi, Tsujita Kenichi, Matoba Tetsuya, Nagai Ryozo

    Circulation Journal   87 ( 2 )   336 - 344   2023年1月   （ ISSN:1346-9843 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本循環器学会  

    冠動脈疾患(CAD)患者の心拍数(HR)、β遮断薬の投与量、予後の関連性を調べた。大学病院6施設と国立循環器病研究センターにて心臓カテーテル法が施行され、Clinical Deep Data Accumulation System(CLIDAS)に登録されたCAD症例8744名のデータを評価した。退院時のHRを指標とし、本集団をQ1(HRが60拍/分未満)からQ4(75拍/分以上)までの四分位群に層別化して解析した。Q1を基準としたQ4の主要有害心脳血管イベント(MACCE)発生ハザード比は、急性冠症候群(ACS)の患者群では1.65(P=0.001)、慢性冠症候群(CCS)群では1.45(P=0.019)となった。β遮断薬の使用に関して(n=4964)、共変量の調整後、ACS群ではβ遮断薬の低用量とMACCEとの有意な関連が示されたが(ハザード比1.41、P=0.012)、CCS群では示されなかった。結論として、退院時のHR 75拍/分以上はACS、CCSのいずれの患者においても転帰不良と関連していた。

  • Histologic Diagnosis of Coronary Amyloidosis Using Percutaneous Transluminal Directional Atherectomy

    Yoshida, D; Hashimoto, T; Katsuki, M; Ishikita, A; Ishikawa, Y; Fujino, T; Shinohara, K; Matsushima, S; Kinugawa, S; Nakano, Y; Katsuki, S; Matoba, T; Hayashidani, S; Tsutsui, H

    CJC OPEN   5 ( 1 )   99 - 102   2023年1月   （ ISSN:2589-790X ）

    　詳細を見る

    記述言語：英語   出版者・発行元：CJC Open  

    DOI： 10.1016/j.cjco.2022.11.009

    Web of Science

    Scopus

    PubMed

  • Association between serum oxysterols and coronary plaque regression during lipid-lowering therapy with statin and ezetimibe: Insights from the CuVIC trial.

    Nakano Y, Yamamoto M, Matoba T, Katsuki S, Nakashiro S, Takase S, Akiyama Y, Nagata T, Mukai Y, Inoue S, Oi K, Higo T, Takemoto M, Suematsu N, Eshima K, Miyata K, Usui M, Sadamatsu K, Kadokami T, Hironaga K, Ichi I, Todaka K, Kishimoto J, Tsutsui H; for the QcVIC Investigators.

    J Atheroscler Thromb.   2022年11月

  • Histologic Diagnosis of Coronary Amyloidosis Using Percutaneous Transluminal Directional Atherectomy.

    Yoshida D, Hashimoto T, Katsuki M, Ishikita A, Ishikawa Y, Fujino T, Shinohara K, Matsushima S, Kinugawa S, Nakano Y, Katsuki S, Matoba T, Hayashidani S, Tsutsui H.

    CJC Open.   2022年10月

  • Percutaneous coil embolization and stent implantation for multiple coronary-to-pulmonary artery fistulas with giant coronary aneurysms; a case report.

    Nakano Y, Matoba T, Nagatomo Y, Tsutsui H.

    Eur Heart J Case Rep.   2022年3月

  • Percutaneous coil embolization and stent implantation for multiple coronary-to-pulmonary artery fistulas with giant coronary aneurysms: a case report

    Nakano, Y; Matoba, T; Nagatomo, Y; Tsutsui, H

    EUROPEAN HEART JOURNAL-CASE REPORTS   6 ( 3 )   ytac104   2022年3月   （ eISSN:2514-2119 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：European Heart Journal - Case Reports  

    Background: Multiple coronary-to-pulmonary artery fistulas (CPAFs) with giant coronary aneurysms (CAs) are extremely rare. The appropriate therapeutic indication and strategy for CPAFs have not been established. Case summary: Herein, we report the case of an asymptomatic 74-year-old woman with multiple CPAFs associated with giant CAs that had gradually developed over a 4-year period. After heart team discussion, we were successfully treated by minimally invasive intervention using transcatheter coil embolization and coronary stent implantation to prevent ruptures. Discussion: Coronary-to-pulmonary artery fistulas required evaluation of the appropriate timing of therapy initiation with reference to the presence of symptoms and fistula and aneurysm sizes, and determination of the optimal therapeutic approach with reference to the anatomy of the fistula with aneurysm and patient background characteristics.

    DOI： 10.1093/ehjcr/ytac104

    Web of Science

    Scopus

    PubMed

  • Comparison of endothelial dysfunction in coronary arteries with bare metal and 2nd-generation drug-eluting stents

    Akiyama, Y; Matoba, T; Katsuki, S; Takase, S; Nakashiro, S; Nakano, Y; Noma, K; Tsutsui, H

    Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ   29 ( 3 )   379 - 392   2022年3月   （ ISSN:13403478 eISSN:18803873 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：一般社団法人 日本動脈硬化学会  

    Aims: Previous studies suggested that implantation with a 1st-generation DES was associated with coronary endothelial dysfunction, which was associated with Rho-kinase activation. Second-generation drug-eluting stents (DESs) may preserve coronary endothelial function in stented coronary arteries; however, because of method-ological limitations, further study is needed to clarify the association between 2nd-generation DESs and coronary endothelial dysfunction. Methods: We retrospectively analysed the CuVIC trial database, where we identified 112 patients who under-went coronary stenting in the left coronary arteries with either a bare metal stent (BMS, n=53) or 2nd-generation DES (n =59). We compared vasomotions of target vessels with stents and non-target vessels without stents. Fur-thermore, we measured the Rho-kinase activation detected in mononucleocytes from aortic and coronary sinus blood. Results: ACh-induced vasoconstrictive responses of target vessels were not enhanced with a 2nd-generation DES (45±21% vs. 44±20%, P=0.56, paired t-test), but significantly enhanced in the coronary arteries with a BMS (50±18% vs. 42±20%, P =0.002). Rho-kinase activation did not differ between patients with a BMS and 2nd-generation DES. In the target vessels with a BMS, large late lumen loss and acute coronary syndrome (ACS) at the index percutaneous coronary intervention (PCI) were associated with ACh-induced enhanced coronary vaso-constrictive responses. Conclusions: Evaluation of ACh-induced vasomotion of target vessels comparing with non-target vessels revealed that 2nd-generation DESs were not associated with coronary endothelial dysfunction in target vessels, nor activation of Rho-kinase in the coronary sinus blood 6-8 months after stenting.

    DOI： 10.5551/jat.61366

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • Comparison of Endothelial Dysfunction in Coronary Arteries with Bare Metal and 2 nd-Generation Drug-Eluting Stents.

    Akiyama Y, Matoba T, Katsuki S, Takase S, Nakashiro S, Nakano Y, Noma K, Tsutsui H.

    J Atheroscler Thromb.   2022年3月

  • ベアメタルステントまたは第2世代薬剤溶出性ステントを留置した冠動脈における内皮機能障害の比較(Comparison of Endothelial Dysfunction in Coronary Arteries with Bare Metal and 2nd-Generation Drug-Eluting Stents)

    Akiyama Yusuke, Matoba Tetsuya, Katsuki Shunsuke, Takase Susumu, Nakashiro Soichi, Nakano Yasuhiro, Noma Kensuke, Tsutsui Hiroyuki

    Journal of Atherosclerosis and Thrombosis   29 ( 3 )   379 - 392   2022年3月   （ ISSN:1340-3478 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本動脈硬化学会  

    左冠動脈の狭窄病変に対してステント留置術を施行した患者112例(男性86例、女性26例)を対象に、ベアメタルステントまたは第2世代薬剤溶出性ステントの留置が冠動脈内皮機能障害に及ぼす影響を比較した。対象はコレステロール吸収阻害薬による冠動脈ステント標的血管の機能改善効果(CuVIC)試験に登録された患者で、標的血管不全を呈した症例は除外した。患者を留置ステントに応じて、ベアメタルステント(BMS)群53例(男性87%、平均64±11歳)と第2世代薬剤溶出性ステント(DES)群59例(男性68%、平均67±9歳)の2群に分類した。患者背景に有意な群間差はなかった。アセチルコリン負荷下でステント留置した標的血管と非標的血管における攣縮性を比較したところ、BMS群は標的血管(50±18%)の方が非標的血管(42±20%)より冠攣縮が有意に高かったが(P=0.002)、DES群で有意差はなかった。大動脈および冠静脈洞で採血した末梢血単核球のRho kinase活性はBMS群とDES群の間に有意差はなかった。BMS群で標的血管における冠攣縮の関連因子として、晩期内腔損失と冠症候群の既往が同定された。

  • PPARγ-targeting Nanomedicine Promotes Cardiac Healing After Acute Myocardial Infarction by Skewing Monocyte/Macrophage Polarization in Preclinical Animal Models.

    Tokutome M, Matoba T, Nakano Y, Okahara A, Fujiwara M, Koga J, Nakano K, Tsutsui H, Egashira K.

    Cardiovasc Res.   2019年1月

  • Successful Intravascular Ultrasound-Guided Transradial Coronary Intervention with a 4Fr Guiding Catheter.

    Nakano Y, Sadamatsu K.

    Case Rep Cardiol   2016年9月

  • The Effect of Low Frame Rate Fluoroscopy on the X-ray Dose during Coronary Intervention.

    Sadamatsu K, Nakano Y.

    Intern Med.   2016年8月

  • Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated Inflammation.

    Nakano Y, Matoba T, Tokutome M, Funamoto D, Katsuki S, Ikeda G, Nagaoka K, Ishikita A, Nakano K, Koga J, Sunagawa K, Egashira K.

    Sci Rep.   2016年6月

  • Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening.

    Ikeda G, Matoba T, Nakano Y, Nagaoka K, Ishikita A, Nakano K, Funamoto D, Sunagawa K, Egashira K.

    Sci Rep.   2016年2月

  • Balloon crushing of a protruding everolimus-eluting stent for isolated coronary stenosis at the side branch ostium.

    Sadamatsu K, Okahara A, Nakano Y, Mine D, Koga Y.

    Int J Cardiol.   2015年11月

  • A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model.

    Nagaoka K, Matoba T, Mao Y, Nakano Y, Ikeda G, Egusa S, Tokutome M, Nagahama R, Nakano K, Sunagawa K, Egashira K.

    PLoS One.   2015年7月

  • Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes.

    Katsuki S, Matoba T, Nakashiro S, Sato K, Koga J, Nakano K, Nakano Y, Egusa S, Sunagawa K, Egashira K.

    Circulation.   2014年2月

▼全件表示

講演・口頭発表等

▼全件表示

MISC

▼全件表示

所属学協会

  • 日本内科学会、日本循環器学会、日本心血管インターベンション治療学会

  • 日本高血圧学会

共同研究・競争的資金等の研究課題

  • 冠動脈CTを用いた石灰化リスクスコアの開発とAI解析による臨床予後予測の検討

    研究課題/領域番号：25K11389  2025年4月 - 2028年3月

    科学研究費助成事業  基盤研究(C)

    仲野 泰啓

    　 詳細を見る

    資金種別：科研費

    CiNii Research

  • 心血管の炎症における酸化ステロールの分子生物学的役割と治療標的の解明

    研究課題/領域番号：23K21434  2021年4月 - 2025年3月

    科学研究費助成事業  基盤研究(B)

    的場 哲哉, 仲野 泰啓, 香月 俊輔, 古賀 純一郎

    　 詳細を見る

    資金種別：科研費

    酸化ステロールはコレステロールが保存や調理による加熱、さらに体内での酸化ストレスによって変性した物質で、心臓や血管に炎症を起こし、動脈硬化や心不全の原因となることが徐々に明らかになってきています。この研究は、臨床研究において、心筋梗塞などの冠動脈疾患患者の血液中の酸化ステロール量と病状の関わりを解明するとともに、基礎研究において、酸化ステロールが心血管病を起こすメカニズムを明らかにし、治療法開発のターゲットを検討しています。

    CiNii Research

教育活動概要

  • 医学部医学科学生の教育：循環器学講義、5年生ベッドサイド、6年生クリニカルクラークシップ
    大学病院スタッフへの教育：心臓カテーテル検査、治療

担当授業科目

  • 循環器内科

    2023年4月 - 2024年3月   通年

専門診療領域

  • 生物系／医歯薬学／内科系臨床医学／循環器内科学

医師免許取得年

  • 2006年